Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex by Generic Manufacturer Teva
The panel ruled that the patents (Nos. 5,466,823 and 5,563,165) covering the active ingredient and a pharmaceutical composition thereof are valid, enforceable and infringed by the generic manufacturer's product. In the same decision, the Court ruled that a third patent (No. 5,760,068) covering the use in the treatment of inflammation was invalid. The decision prohibits Teva from launching a competitor drug in the U.S. until May 2014. Either party may request a rehearing by the Court of Appeals or a review by the U.S. Supreme Court. Celebrex was approved by the FDA in 1998. Its sales totaled $1.7 billion the U.S. in 2007.
Chris Loder, 212-733-7897
Suzanne Harnett, 212-733-8009
Posted: March 2008